Four Czech and Slovak tycoons buy Poland's Gemini pharmacy chain
What's the deal? Four Czech and Slovak investment groups — Penta InvestmentsDealroom has a profile for this one. Try Dealroom →, Sev.enDealroom has a profile for this one. Try Dealroom →, Creditas, and J&T-linked Auctor Holding — have jointly bought Gemini Polska, one of Poland's largest pharmacy chains. Each holds exactly 25%. The sellers were American private equity fund Warburg Pincus, which had owned the chain for a decade.
Why the split? Poland's "Pharmacy for the Pharmacist" rules limit concentrated ownership in the pharmacy sector, and the restrictions have been contested and revised in recent years. By each taking a quarter and declaring mutual independence, the buyers structured the purchase as dispersed rather than controlled by any single group.
Who's buying? Pavel Tykač's Sev.en focuses on energy and mining; Forbes put his 2026 fortune at 188 billion crowns. Marek Dospiva's Penta operates in healthcare, real estate, and financial services, with assets including the Dr. MaxDealroom has a profile for this one. Try Dealroom → pharmacy chain, bookmaker FortunaDealroom has a profile for this one. Try Dealroom →, and Penta HospitalsDealroom has a profile for this one. Try Dealroom →. The Hubáček family's Creditas and J&T-linked Auctor complete the group — Patrik Tkáč's family holds roughly 12% through Auctor.
What could go wrong? Penta backs Dr. Max, which runs more than 500 Polish pharmacies, so one owner is already a major competitor. The investors say Gemini will remain independent, but regulatory and legal disputes over Poland's pharmacy rules continue.
What's the endgame? Gemini has secured 1 billion zlotys in bank financing for refinancing and expansion, giving the new owners a platform to grow in a market where rivals operate under tight constraints.
The signal: The deal marks one of the largest pharmacy transactions in Poland in years, bringing together four separate Czech and Slovak investment groups — each taking an equal stake — in a single foreign purchase. It illustrates how investors are structuring deals around Poland's evolving pharmacy-ownership rules, in a sector where one of the four buyers, Penta, is already a major competitor through its Dr. Max chain.
Read more: byteseu.com
Image credit: My name's axel
